Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Verici Dx Plc ( (GB:VRCI) ).
Verici Dx plc has published a Circular seeking shareholder approval to issue new Ordinary Shares on a non-pre-emptive basis, as part of a proposed fundraising initiative. This fundraising aims to accelerate the company’s commercial growth and support the scaling up of revenues for its Tutivia™ product, following the recent securing of Medicare Coverage. The company anticipates that existing allotment authorities will be insufficient for the proposed fundraising, which is expected to involve a placing with institutional and other investors. The size and structure of the fundraising are yet to be determined, and further updates will be provided in due course.
More about Verici Dx Plc
Verici Dx plc is a developer of advanced clinical diagnostics focused on organ transplants, particularly kidney transplants. The company offers a suite of leading-edge tests that utilize artificial intelligence-assisted transcriptomic analysis to provide RNA signatures. These tests help assess patient and organ response risks, aiding clinicians in improving patient outcomes. Verici Dx’s technology focuses on immune response and other biological pathways critical for transplant prognosis, and the company collaborates with medical device, biopharmaceutical, and data science partners to drive innovation.
Average Trading Volume: 1,343,166
Technical Sentiment Signal: Sell
Current Market Cap: £3.94M
For an in-depth examination of VRCI stock, go to TipRanks’ Stock Analysis page.